clobetasol and Conjunctivitis

Clobetasone butyrate (0.1%), a new topical corticosteroid eye preparation for the treatment of ocular inflammation, has been compared with sodium cromoglycate (2%) eye drops in thirty-nine patients experiencing allergic conjunctivitis during the hay fever season. In this double-blind, within-patient comparative study both preparations were effective in relieving the patients' symptoms of conjunctivitis. However, clobetasone butyrate was clinically more effective than sodium cromoglycate as determined by symptom score card analysis (P less than 0.01) and the patients' overall assessment of treatment (P less than 0.05). Patients' preference for the treatment of seasonal allergic conjunctivitis was markedly in favour of clobetasone butyrate (P less than 0.001).

Topics: Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Child; Clinical Trials as Topic; Clobetasol; Conjunctivitis; Cromolyn Sodium; Double-Blind Method; Female; Humans; Male; Middle Aged; Rhinitis, Allergic, Seasonal

The effect of clobetasone butyrate eye drops on ocular pressure was tested in 15 steroid responders suffering from different types of conjunctivitis and compared with betamethasone eye drops. Elevated intraocular pressure following application of 0.1% betamethasone eye drops decreased significantly within 2 weeks under medication with 0.1% clobetasone butyrate 4 times daily, whereas fellow eyes kept under treatment with betamethasone suffered further increases in IOP. The therapeutic effect and subjective compatibility of the two steroids were found to be approximately equal.

Topics: Betamethasone; Clobetasol; Conjunctivitis; Humans; Intraocular Pressure; Ophthalmic Solutions